Impact of pembrolizumab on health outcomes and productivity in earlier-stage cancers within the US Medicare population
Perioperative/adjuvant pembrolizumab in earlier-stage cancers can meaningfully improve clinical outcomes for Medicare patients and reduce caregiver productivity losses. Sustained investment and access to pembrolizumab are critical to fully realize these benefits for patients and society.
Authors
- Sameer A. Greenall (ORCID: https://orcid.org/0000-0002-1461-7111)
- Joe Taylor (ORCID: https://orcid.org/0000-0002-4502-0860)
- Yizhen Lai
- Catarina Neves
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Utrecht University (NL)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-12-13
- DOI
- https://doi.org/10.1080/13696998.2025.2599670
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00